ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026
[The Influence of Hepatitis B Virus on Sex Hormone Levels and Quality of Life in Female Hepatitis B Patients With Different Alanine Aminotransferase States].
Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study examines the effects of hepatitis B virus on sex hormone levels, menopause, sleep, depression, anxiety, and quality of life in female hepatitis B patients under different alanine aminotransferase (ALT) conditions. Methods: A total of 306 female patients with chronic hepatitis B, exhibiting different viral loads and varying ALT statuses, were randomly selected for stratified sampling. The effects of hepatitis B virus on sex hormone levels, menopause, sleep, depression, anxiety, and quality of life were compared and analyzed across different ALT statuses. Among these, 110 female patients with chronic hepatitis B and ALT levels ≥ 2 times the upper limit of normal received antiviral treatment and were followed for 24 weeks. Changes in the above indicators before and after antiviral treatment were compared and analyzed. Results: In the ALT-normal group and the group with ALT levels ≤ 2 times the upper limit of normal, there was no significant difference in the effects of different hepatitis B virus viral loads on sex hormone levels, menopause, sleep, depression, anxiety, or quality of life in female patients with chronic hepatitis B. However, in the group with ALT ≥ 2 times the upper limit of normal, as the viral load increased (from the low replication group to the high replication group), the estradiol concentration decreased from (84.20 ± 7.78) pg/mL to (64.60 ± 9.18) pg/mL, testosterone increased from (0.33 ± 0.02) ng/mL to (0.45 ± 0.04) ng/mL, follicle-stimulating hormone increased from (47.82 ± 7.62) mIU/mL to (59.68 ± 7.19) mIU/mL, the menopause rate increased from 55.56% to 86.11%, the Pittsburgh Sleep Quality Index increased from 11.02 ± 0.52 to 15.93 ± 0.71, the Self-Rating Anxiety Scale score increased from 46.06 ± 4.92 to 64.66 ± 6.18, the Self-Rating Depression Scale score increased from 44.14 ± 5.47 to 67.08 ± 4.57, and all dimensions of quality of life significantly decreased, with all differences being statistically significant ( Conclusion: The impact of hepatitis B virus on female patients varies under different ALT conditions. For patients with ALT levels at or above twice the upper limit of normal, actively initiating antiviral treatment can significantly improve sex hormone levels and various physiological and psychological indicators in female patients, thereby enhancing their quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.